262 related articles for article (PubMed ID: 36982699)
1. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
[TBL] [Abstract][Full Text] [Related]
2. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
3. The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain.
Minderman M; Lantermans H; van der Zwaan C; Hoogendijk AJ; van den Biggelaar M; Kersten MJ; Spaargaren M; Pals ST
Blood Cancer J; 2023 Aug; 13(1):125. PubMed ID: 37591861
[TBL] [Abstract][Full Text] [Related]
4. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
5. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
[TBL] [Abstract][Full Text] [Related]
7. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
8. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.
Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W
Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184
[TBL] [Abstract][Full Text] [Related]
9. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
10. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
[TBL] [Abstract][Full Text] [Related]
11. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
[TBL] [Abstract][Full Text] [Related]
12. Absence of Non-Canonical, Inhibitory
Cardona Gloria Y; Bernhart SH; Fillinger S; Wolz OO; Dickhöfer S; Admard J; Ossowski S; Nahnsen S; Siebert R; Weber ANR
Front Immunol; 2021; 12():616451. PubMed ID: 34163463
[TBL] [Abstract][Full Text] [Related]
13. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
Seltzer J; Moorad R; Schifano JM; Landis JT; Dittmer DP
J Virol; 2020 May; 94(10):. PubMed ID: 32161170
[TBL] [Abstract][Full Text] [Related]
15. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.
Yu X; Li W; Deng Q; Liu H; Wang X; Hu H; Cao Y; Xu-Monette ZY; Li L; Zhang M; Lu Z; Young KH; Li Y
Blood; 2021 Mar; 137(12):1615-1627. PubMed ID: 33025009
[TBL] [Abstract][Full Text] [Related]
16. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
[TBL] [Abstract][Full Text] [Related]
17. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
[TBL] [Abstract][Full Text] [Related]
19. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
20. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
